<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Transplant International | New and Recent Articles</title>
        <link>https://www.frontierspartnerships.org/journals/transplant-international</link>
        <description>RSS Feed for Transplant International | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-06-19T18:09:16.310+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15840</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15840</link>
        <title><![CDATA[Cold ischemia time exceeding 12 hours is a risk factor for delayed graft function and increased mortality in kidney transplant recipients within the eurotransplant senior program]]></title>
        <pubdate>2026-06-17T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Laura Matuschik</author><author>Lisa André</author><author>Philipp A. Holzner</author><author>Dietrich A. Ruess</author><author>Yakup Tanriver</author><author>Johanna Schneider</author><author>Bernd Jänigen</author>
        <description><![CDATA[With the age of those awaiting kidney transplantation (KTx) increasing, the Eurotransplant Senior Program (ESP) reduces median waiting time by > 1.5 years for patients aged ≥65 compared to standard allocation and doubles life expectancy compared with remaining on dialysis. However, older-donor organs are more vulnerable to prolonged cold ischemia time (CIT). To minimize CIT, both kidneys from one donor are regionally allocated, in our case, to a single transplant center. This study assesses the impact of CIT on delayed graft function (DGF) and long-term outcomes in consecutively transplanted ESP recipients from the same donor. We retrospectively analyzed 208 ESP KTx at Freiburg Transplant Center (1999–2019), focusing on 74 consecutively transplanted kidney pairs (recipients ranked “1” or “2”). DGF incidence was similar for rank 1 and rank 2 recipients. CIT >12 h significantly increased DGF risk versus CIT <8 h (adjusted OR 6.30; 95% CI 1.52–26.06; p = 0.011). Death-censored allograft survival was unaffected, but CIT >12 h tripled mortality risk (adjusted HR 3.19; 95% CI 1.44–7.49; p = 0.005). Consecutive transplantation does not disadvantage the second recipient if CIT remains <12 h. CIT >12 h independently predicts DGF and higher mortality, emphasizing the need to minimize ischemia time.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16976</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16976</link>
        <title><![CDATA[Can european law keep pace with biomedical innovation? The reinvention of transplantation regulation]]></title>
        <pubdate>2026-06-16T00:00:00Z</pubdate>
        <category>News and Views</category>
        <author>Olivier Thaunat</author><author>Frank J. M. F. Dor</author><author>Umberto Cillo</author><author>Gabriel C. Oniscu</author><author>Ekaterine Berishvili</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16406</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16406</link>
        <title><![CDATA[Sex-related differences in survival based on [18F]FDG PET/CT metabolic tumor volume after liver transplantation for colorectal liver metastases]]></title>
        <pubdate>2026-06-16T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Nadide Mutlukoca Stern</author><author>Svein Dueland</author><author>Pål-Dag Line</author><author>Trygve Syversveen</author><author>Harald Grut</author>
        <description><![CDATA[[18F]FDG PET/CT-derived metabolic tumor volume (MTV) is a strong prognostic biomarker in patients undergoing liver transplantation (LT) for non-resectable colorectal liver metastases (nCRLM). This study aimed to evaluate whether MTV-based survival outcomes after LT for nCRLM differ between males and females. Patients who underwent LT for nCRLM between 2006 and 2022 were included (n = 45). Baseline characteristics were compared using the Mann–Whitney U test and Fisher’s exact test. Overall survival (OS), disease-free survival (DFS), and survival after relapse (SAR) were estimated using Kaplan–Meier analysis with the log-rank test. Cox regression analyses including sex, dichotomized MTV, and an interaction term between sex and MTV were performed. Female patients had significantly shorter OS compared with male patients (median 58 vs. 92 months, p = 0.047). Low MTV was associated with significantly longer OS, DFS and SAR in both sexes. Among patients with high MTV, females had significantly shorter OS than males (median 25 vs. 59 months, p < 0.001). Females had more non-pulmonary recurrences than males (p = 0.006) and shorter median SAR than males (17 vs. 46 months, p < 0.001) with high MTV. A significant interaction between sex and MTV was observed, indicating a particularly adverse prognostic impact of high MTV in female patients.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16447</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16447</link>
        <title><![CDATA[Regulatory approach to manipulated organs in Europe: preserving human organs as non-commercial goods ]]></title>
        <pubdate>2026-06-16T00:00:00Z</pubdate>
        <category>Point of View</category>
        <author>Natividad Cuende</author><author>Ander Izeta</author><author>Beatriz Domínguez-Gil</author>
        <description><![CDATA[We welcome the European Commission’s initiative to amend the European Organ Directive within the framework of the proposed Biotech Act, intended to align it with recent scientific and technological advances, particularly organ manipulations aimed at improving transplant outcomes and human health. However, the amendment introduces a definition of organ processing that raises significant regulatory questions, particularly related to the exclusions it contains, which might allow human organs subjected to genetic or enzymatic manipulation to be regulated as medicinal products or as goods under industrial or commercial legal frameworks. The potential consequences of regulating human organs as medicines are reviewed, and awareness is raised of the risk of undermining the altruistic basis of donation and public trust in organ donation and transplantation systems. Moreover, this shift could jeopardise access to this life-saving therapy and threaten the economic sustainability of healthcare systems. Concurrently, potential risks associated with certain forms of manipulation (e.g., genetic modification of organs) must be rigorously assessed before their incorporation into clinical practice. We propose a distinctly European regulatory model that preserves the intrinsic value of human organs, promotes collaboration between medicines and transplant authorities, and enables biomedical innovation through companies providing services and technical solutions to healthcare systems.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16526</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16526</link>
        <title><![CDATA[Delayed graft function and long-term outcomes after deceased donor kidney transplantation: insights from mate-kidney analysis]]></title>
        <pubdate>2026-06-16T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Oscar A. Garcia Valencia</author><author>Ahmed Zeen Alabedeen Alrifai</author><author>Mohammed Y. Mahgoub</author><author>Girish Mour</author><author>Byron Smith</author><author>Andrew J. Bentall</author><author>Naim S. Issa</author><author>Caroline C. Jadlowiec</author><author>Alexander R. Cortez</author><author>Hatem Amer</author><author>Samy Riad</author>
        <description><![CDATA[Delayed graft function (DGF) is a frequent complication after deceased donor kidney transplantation, yet its long-term impact remains understudied. Heterogeneous populations, short follow-up, and inadequate control of donor-related factors have limited prior studies. Using the Scientific Registry of Transplant Recipients (2005–2024), we evaluated the association between DGF and long-term graft outcomes, including a mate-kidney (same donor, discordant DGF status) analysis to isolate its independent effect. We identified 103,678 dialysis-dependent deceased donor kidney recipients maintained on tacrolimus and mycophenolate. Mixed-effects Cox models, adjusted for donor, recipient, immunologic, and procurement factors. DGF occurred in 30.1% of recipients and was associated with increased death-censored graft failure (HR 1.40; 95% CI 1.33–1.47) and overall graft failure (HR 1.27; 95% CI 1.23–1.31). DGF recipients had higher rejection rates at 6 (6.0% vs. 4.7%) and 12 months (8.9% vs. 7.3%), longer hospital stay, and higher 1-year rehospitalization. In the mate-kidney analysis (6,818 donors), DGF remained strongly associated with death-censored graft failure (HR 1.58; 95% CI 1.39–1.80) and overall graft failure (HR 1.35; 95% CI 1.25–1.46), confirming the independent effect of DGF. DGF is a strong predictor of adverse long-term outcomes irrespective of rejection and warrants targeted prevention strategies and intensified follow-up.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16339</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16339</link>
        <title><![CDATA[Elevated filling pressures are associated with poor long-term graft survival after pediatric heart transplantation]]></title>
        <pubdate>2026-06-15T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Ezgi Yavasca</author><author>Lisa-Maria Rosenthal</author><author>Regina Stegherr</author><author>Levin Wiebelt</author><author>Isabell Just-Lauer</author><author>Peter Kramer</author><author>Friederike Danne</author><author>Felix Schoenrath</author><author>Frank Konietschke</author><author>Mustafa Yigitbasi</author><author>Felix Berger</author><author>Katharina R. L. Schmitt</author><author>Oliver Miera</author><author>Fatima I. Lunze</author>
        <description><![CDATA[Long-term survival has improved in the current era of pediatric heart transplantation (HT). The impact of elevated filling pressures [EFP; defined as pulmonary capillary wedge pressure (PCWP) > 15 mmHg and/or right atrial pressure (RAP) > 12 mmHg in the absence of biopsy-confirmed rejection] on long-term outcomes beyond 10 years remains poorly characterized. We assessed whether EFP during the early years after HT are associated with poor graft survival and cardiovascular adverse events (AE). We retrospectively analyzed 114 pediatric HT grafts (1986–2020) with available PCWP and/or RAP measurements 7 months to 5 years post-transplant (grouping period), representing a landmark cohort of 5-year survivors. Associations of EFP with graft survival and AE were evaluated. Fourteen grafts (12%) had EFP during the grouping period. Grafts with EFP had significantly worse long-term survival (44% vs. 85% at 10 years; log-rank p < 0.001), and higher risk of graft loss (overall HR 6.04, 95% CI [2.01–16.85]). The incidence of AE was numerically higher in grafts with EFP (26.6 [15.2–43.2] vs. 11.9 [9.4–14.9] per 100 person-years), but should be interpreted as exploratory. EFP within the early years post-transplant are associated with poor graft survival and may indicate cardiovascular complications.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16461</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16461</link>
        <title><![CDATA[Not all antibodies are created equal: total IgG glycosylation and severity of antibody-mediated rejection in kidney transplantation]]></title>
        <pubdate>2026-06-12T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Johan Noble</author><author>Leandre M. Glendenning</author><author>Celine Dard</author><author>Anne Bourdin</author><author>Marta Crespo</author><author>Umberto Maggiore</author><author>Ari R. Inwood</author><author>Grace C. Carlson</author><author>Brian A. Cobb</author><author>Paolo Cravedi</author>
        <description><![CDATA[Antibody-mediated rejection (AMR) is a leading cause of kidney transplant failure and is primarily driven by donor-specific anti-HLA antibodies (DSA), although DSA presence alone does not fully explain the heterogeneity of AMR severity. We prospectively studied 79 kidney transplant recipients from 2 European centers, including 29 with active AMR (aAMR), 29 with chronic-active AMR (caAMR), and 21 controls without rejection, to investigate the association between total Immunoglobulin-G (IgG) glycosylation profiles and AMR. IgG glycosylation was quantified using lectin-based ELISA, assessing relative levels of mannose, core fucose, α2,6-linked sialic acid, and bisecting N-acetylglucosamine (GlcNAc). Bisecting GlcNAc levels were higher in caAMR compared with controls and aAMR (both p < 0.001), while core fucosylation and mannose levels were increased in aAMR and caAMR relative to controls. Higher levels of core fucose, mannose, and α2,6-sialylation were associated with increasing glomerulitis severity. We found that bisecting GlcNAc (PHA-E/Fc) was significantly associated with both higher g- and cg-score (in ordinal models, OR = 2.1 [95% CI: 1.2–4.1; p = 0.017], and OR = 2.0 [95% CI: 1.1–4.3; p = 0.046], respectively). Mannose level (ConA/Fc) was significantly associated with higher g-score (2.1 [1.1–4.2], p = 0.017]). These findings indicate that distinct total IgG glycosylation features are independently associated with specific histological patterns of AMR severity.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16147</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16147</link>
        <title><![CDATA[Implementation of a controlled DCD program in Western Austria – key considerations and insights]]></title>
        <pubdate>2026-06-12T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Felix J. Krendl</author><author>Silvia Oberparleiter</author><author>Florian Ponholzer</author><author>Franka Messner</author><author>Stefan Scheidl</author><author>Manuel Maglione</author><author>Annemarie Weissenbacher</author><author>Thomas Resch</author><author>Rupert Oberhuber</author><author>Lukas Stastny</author><author>Julia Dumfarth</author><author>Clemens Seelmaier</author><author>Wolfgang List</author><author>Ronny Beer</author><author>Benno Cardini</author><author>Stefan Schneeberger</author><author>Stephan Eschertzhuber</author>
        <description><![CDATA[Controlled donation after circulatory death (cDCD) offers an opportunity to expand the deceased donor pool, yet implementation remains limited in many countries. We conducted a retrospective single-center analysis of all cDCD donors (Maastricht category III) referred to the Transplant Center at the Medical University of Innsbruck between January 1, 2018, and December 31, 2024. Donor characteristics, ischemia times, organ utilization, and program-level trends were analyzed. In addition, key steps and protocols essential for establishing a cDCD program were systematically evaluated. Of 56 referred cDCD donors, 53 (94.6%) proceeded to organ recovery (i.e., actual donors), and 42 (75.0%) resulted in the transplantation of at least one organ (i.e., utilized donors). Utilized donors had significantly lower BMI than non-utilized donors (25 vs. 31 kg/m2, p = 0.003). The median functional warm ischemia time was 26 min (IQR 23–28). The mean number of transplanted organs per donor was 2.06. Organ utilization rates were highest for kidneys (60.4%). Nationwide DCD activity increased from 3% to 18% following the implementation of a structured cDCD program in Western Austria. In summary, we have outlined steps and protocols required to successfully implement a cDCD program, resulting in high utilization rates and a measurable impact on national cDCD activity.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.14920</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.14920</link>
        <title><![CDATA[Incidence and factors associated with Herpes Zoster infection in kidney transplant recipients, a recent epidemiological study]]></title>
        <pubdate>2026-06-10T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Benjamin Taton</author><author>Pierre Pfirmann</author><author>Isabelle Garrigue</author><author>Karine Moreau</author><author>Marine Novion</author><author>Frédéric Jambon</author><author>Pierre Merville</author><author>Lionel Couzi</author><author>Hannah Kaminski</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16549</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16549</link>
        <title><![CDATA[Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease]]></title>
        <pubdate>2026-06-10T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Karim Tazibet</author><author>Vincent Bunel</author><author>Hervé Mal</author><author>Tiphaine Goletto</author><author>Pierre Halitim</author><author>Lise Morer</author><author>Domitille Mouren</author><author>Mathilde Salpin</author><author>Adèle Sandot</author><author>Gaëlle Weisenburger</author><author>Philippe Montravers</author><author>Enora Atchade</author><author>Sébastien Tanaka</author><author>Justine Frija</author><author>Linda Hajouji</author><author>Yves Castier</author><author>Pierre Mordant</author><author>Bruno Crestani</author><author>Raphaël Borie</author><author>Kinan El Husseini</author>
        <description><![CDATA[Fibrosing interstitial lung diseases (ILDs) are the leading cause of lung transplantation (LTx), with worse results than other indications. We hypothesised that exposure to non-steroidal immunosuppressive agents (IAs) in the year preceding LTx for ILD may result in poorer early outcomes. We retrospectively analysed adults who underwent LTx for ILD from April 2011 to June 2024 in our institution and compared patients who received IA within 1 year before LTx to those who did not (systemic steroids exposure was used to adjust analysis). The primary outcome was 12-month retransplantation-free survival. Among 209 patients included, 76 (36%) had received IA within 1 year of LTx, and these patients had significantly worse 12-month retransplantation-free survival on multivariate analysis (62% vs. 80%; HR 1.99, 95%CI [1.11–3.56], p = 0.022); IA exposure increased the odds of grade 3 PGD (OR 3.20 [1.42–7.45], p = 0.005), bronchovascular fistula (OR 9.43, 95% CI [1.48–183], p = 0.042), pneumonia episodes in the first 6 months (median 2 [IQR 1-4] vs. 1 [0.5–2.5], p = 0.001), cytomegalovirus viremia under prophylaxis (21% vs. 5.2%, p = 0.005) and incidence of ganciclovir-resistant cytomegalovirus (14% vs. 3.2%, p = 0.021). In conclusion, IA exposure in the year before LTx leads to early complications and worse 12-month survival.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16693</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16693</link>
        <title><![CDATA[Daratumumab as rescue therapy in refractory recurrent FSGS after kidney transplantation: a case series]]></title>
        <pubdate>2026-06-10T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Parthenopi Despina Avaniadi</author><author>Aylin Akifova</author><author>Eva Vanessa Schrezenmeier</author><author>Sophie Lüdemann</author><author>Georgios Eleftheriadis</author><author>Ayse Selin Güneytepe</author><author>Linde Gao</author><author>Friederike Bachmann</author><author>Felicitas E. Hengel</author><author>Anne Mühlig</author><author>Nicola M. Tomas</author><author>Tobias B. Huber</author><author>Kai-Uwe Eckardt</author><author>Klemens Budde</author><author>Fabian Halleck</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16911</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16911</link>
        <title><![CDATA[Editorial: Current developments in artificial organs and engineered ex-situ perfused organs]]></title>
        <pubdate>2026-06-09T00:00:00Z</pubdate>
        <category>Special Issue Editorial</category>
        <author>Cristiano Amarelli</author><author>Jutta Arens</author><author>Cécile Legallais</author><author>Thierry Berney</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17003</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17003</link>
        <title><![CDATA[CD8 regulatory T cell therapy in transplantation: a new path to clinical success?]]></title>
        <pubdate>2026-06-09T00:00:00Z</pubdate>
        <category>News and Views</category>
        <author>Yannick D. Muller</author><author>Julien Zuber</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16181</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16181</link>
        <title><![CDATA[Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report]]></title>
        <pubdate>2026-06-08T00:00:00Z</pubdate>
        <category>Meeting Report</category>
        <author>Ellen Dobrijevic</author><author>Anita van Zwieten</author><author>Allison Jaure</author><author>Armando Teixeira-Pinto</author><author>Sergio A. Acuna</author><author>Curie Ahn</author><author>Eric Au</author><author>Christopher Blosser</author><author>Jonathan C. Craig</author><author>Dale Coghlan</author><author>Bianca Davidson</author><author>Beatriz Dominguez-Gil Gonzalez</author><author>Anna Francis</author><author>Chandana Guha</author><author>Martin Howell</author><author>Anastasia Hughes</author><author>Kenar D. Jhaveri</author><author>Kenneth A. Newell</author><author>Jolanta Malyszko</author><author>Alejandra Mena-Gutierrez</author><author>Naoka Murakami</author><author>Colm O'Reilly</author><author>Javier Recabarren-Silva</author><author>Dharshana Sabanayagam</author><author>Nicole Scholes-Robertson</author><author>Amanda Sluiter</author><author>Helio Tedesco Silva Junior</author><author>Andrea K. Viecelli</author><author>Germaine Wong</author>
        <description><![CDATA[Cancer is a critically important outcome for kidney transplant recipients that inconsistently and infrequently reported in trials. We convened a consensus workshop to establish a core outcome measure for cancer for trials in kidney transplant recipients. Workshop attendees included 21 transplant recipients, 2 caregivers and 46 health professionals from 12 countries. Transcripts were analyzed thematically. Three themes were identified. “Fear of cancer occurrence due to immunosuppression” reflected the psychological burden and uncertainties when balancing suppression with long-term cancer risk. “Capturing the details of type, stage and recurrence”, encompassed recognizing the differential consequences of cancer types, delineating the stage of cancer to convey severity, and distinguishing recurrent from de novo cancer. “Recognizing the challenges of capturing cancer events” included under-reporting and incomplete documentation of longer-term outcomes, variability in cancer screening practices, and absence of coordinated trial networks to support harmonization and aggregation of cancer outcomes across studies. Participants agreed that occurrence, with stratification by cancer type, stage, and recurrence, where possible, would be a practical and meaningful core outcome measure for cancer. Consistent reporting of cancer using a standardized core outcome measure may help to improve the consistency and relevance of trial findings and assist in shared decision-making in kidney transplantation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16347</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16347</link>
        <title><![CDATA[Integrating senotherapeutics into transplantation: liver reconditioning in an aging donor pool]]></title>
        <pubdate>2026-06-08T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Madita L. Buch</author><author>Hannah Esser</author><author>Himath Perera</author><author>Runshi Zheng</author><author>Sofia Ferreira-Gonzalez</author><author>Stuart J. Forbes</author>
        <description><![CDATA[Our aging population is reshaping transplantation medicine. As demand for liver transplantation continues to rise, an aging donor pool presents unique challenges, with marginal organs becoming increasingly prevalent and representing a critical yet underexploited opportunity. Current selection criteria, such as chronological age, may not fully capture organ quality. A multidimensional approach that better reflects true biological aging is now more crucial than ever. Increasing evidence indicates that senescence, a hallmark of aging, influences multiple stages of transplantation, including organ procurement and preservation. Assessing senescence could provide an objective metric for evaluating organ quality. Importantly, senescence quantification could both define organ quality and guide interventions aimed at mitigating this phenomenon. This review explores the contribution of senescence to the transplant process and evaluates emerging opportunities for senescence-based assessment and therapeutic intervention. We also highlight the potential to integrate these strategies with ex vivo machine perfusion to quantify senescence burden, deliver targeted interventions, and functionally recondition marginal grafts, thereby expanding the donor pool and improving outcomes in an aging population.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16284</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16284</link>
        <title><![CDATA[Establishing standards for controlled donation after circulatory determination of death in adults: the Bucharest international European Society for Organ Transplantation consensus]]></title>
        <pubdate>2026-06-04T00:00:00Z</pubdate>
        <category>Consensus Report</category>
        <author>Helen Opdam</author><author>Alicia Pérez-Blanco</author><author>Dale Gardiner</author><author>Richard Hasz</author><author>Nichon Esther Jansen</author><author>Matthieu Le Dorze</author><author>Alberto Sandiumenge</author><author>Giuliano Testa</author><author>Shih-Ning Then</author><author>Marinella Zanierato</author><author>Beatriz Domínguez-Gil</author><author>Gabriel C. Oniscu</author><author>Umberto Cillo</author><author>Dominique E. Martin</author>
        <description><![CDATA[Controlled donation after circulatory determination of death (cDCDD) is increasingly vital to expanding deceased organ donation globally, yet variability exists in clinical, legal, and ethical practices. This study utilized a Delphi consensus process involving 37 international experts to develop recommendations to guide the development and operation of adult cDCDD programs. Two survey rounds evaluated agreement on system requirements, donor identification, medical suitability, communication, end-of-life care, and ante-mortem interventions. Consensus was achieved on numerous recommendations emphasizing the need for robust legal frameworks distinct from end-of-life care decisions, multidisciplinary approaches for donor suitability assessment, and clear, sensitive communication led by trained donation professionals. Ensuring patient comfort and dignity during withdrawal of life-sustaining measures, alongside optimizing donation outcomes, was prioritized. Use of ante-mortem interventions was deemed to require careful balancing of benefits and burdens in line with patient and family preferences. The findings highlight international variability and underscore the importance of tailored protocols, education, and further research to establish an evidence base for ante-mortem interventions and improve clinical prediction of donation feasibility. These consensus recommendations aim to advance ethical, effective, and sustainable adult cDCDD programs worldwide.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16186</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16186</link>
        <title><![CDATA[Serum α-Klotho and SIRT1 - Relationship with graft function, inflammation and hospitalization rates in kidney transplant recipients]]></title>
        <pubdate>2026-06-02T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Anna Sączek</author><author>Krzysztof Batko</author><author>Małgorzata Banaszkiewicz</author><author>Jolanta Małyszko</author><author>Ewa Koc-Żórawska</author><author>Marcin Żórawski</author><author>Jacek Małyszko</author><author>Karolina Niezabitowska</author><author>Katarzyna Sobczyńska</author><author>Przemysław Miarka</author><author>Alina Bętkowska-Prokop</author><author>Katarzyna Krzanowska</author><author>Marcin Krzanowski</author>
        <description><![CDATA[Emerging evidence indicates kidney transplant recipients (KTRs) suffer from accelerated cellular aging, low-grade inflammation and variable degrees of allograft dysfunction. These pathobiological processes shape chronic kidney disease in the graft, for which α-Klotho is being explored as a candidate peptide marker for risk stratification. In this observational cohort study, we recruited 127 KTRs in outpatient care at the University Hospital in Kraków, Poland between September 2016 and June 2019. Serum α-Klotho, sirtuin-1 (SIRT1), and high-sensitivity interleukin-6 (hsIL-6) were assayed using ELISA kits in KTRs and 32 healthy controls (HCs). Thereafter, we utilized crude, age-adjusted, and fully adjusted Firth Poisson regression models with robust standard errors to evaluate predictors of all-cause hospitalization. We observed that circulating α-Klotho was reduced in KTRs, as compared with HCs (median 616 vs. 1,042 pg/mL, P < 0.001). Further, α-Klotho was moderately associated with eGFR at baseline (rho = 0.30) and final follow-up (rho = 0.29). In contrast, α-Klotho was inversely correlated with hsIL-6 (rho = −0.39, 95% CI −0.60–0.15, P = 0.002). In multivariable linear regression models, ln (α-Klotho) changes were tied to higher final eGFR (14.8 95% CI 6.2–25.6 mL/min/1.73 m2). During follow-up of 274 person-years, we recorded 153 hospitalizations. In multivariable models, higher ln (α-Klotho) was independently associated with lower hospitalization rate (IRR 0.31, 95% CI 0.15–0.65, P = 0.002). This association persisted after adjustment for baseline eGFR (IRR 0.37, 95% CI 0.20–0.69, P = 0.002). Overall, given further validation and standardization of assay technology, serum α-Klotho may be a strong candidate for supplemental, outpatient risk stratification in KTRs.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15318</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15318</link>
        <title><![CDATA[Comparable outcomes with anti-thymocyte globulins versus basiliximab in kidney transplantation from controlled circulatory death donors]]></title>
        <pubdate>2026-06-01T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Martin Deslais</author><author>Alice Koenig</author><author>Fanny Buron</author><author>Gabriel Ouellet</author><author>Maud Rabeyrin</author><author>Cécile Picard</author><author>Frédérique Dijoud</author><author>Renaud Snanoudj</author><author>Mohamad Zaidan</author><author>Florent von Tokarski</author><author>Arwa Jalal Eddine</author><author>Moglie Le Quintrec</author><author>Jean-Emmanuel Serre</author><author>Alice Corbel</author><author>Adrien Flahault</author><author>Magali Giral</author><author>Christophe Masset</author><author>Dany Anglicheau</author><author>Olivier Aubert</author><author>Antoine Sicard</author><author>Clément Gosset</author><author>Carmen Lefaucheur</author><author>Gillian Divard</author><author>Christophe Mariat</author><author>Quentin Monchal</author><author>Xavier Matillon</author><author>Anne-Claire Lukaszewicz</author><author>Valérie Dubois</author><author>Emmanuel Morelon</author><author>Olivier Thaunat</author><author>Xavier Charmetant</author>
        <description><![CDATA[Due to organ shortage, donation after circulatory death (DCD) has increased. As DCD kidney grafts have higher rates of delayed graft function (DGF), the French national protocol mandates the use of hypothermic machine perfusion and routine anti-thymocyte globulin (ATG) induction therapy. However, evidence favoring ATG over interleukin-2 receptor antagonists, such as basiliximab, remains scarce. We retrospectively analysed a single-center cohort of 158 low immunological risk patients who underwent DCD kidney transplantation between 2015 and 2023. Patients transplanted before March 2020 received ATG (n = 64), while those transplanted thereafter (during and after the COVID-19 pandemic) received basiliximab (n = 94). Baseline characteristics were comparable, except for recipient age (lower in the basiliximab group), and cold ischemia times were similar. There were no differences in primary non-function, DGF rates (17% after ATG versus 12% after basiliximab), biopsy-proven rejection, one-year renal function or graft survival. ATG was associated with prolonged EBV and BK viremia without increased complications. Hospital stays were similar, but ATG induction was 1.7 times more expensive. These findings were confirmed in an independent French multicenter cohort (n = 506). In conclusion, basiliximab appears to be a cost-effective alternative to ATG for low-immunological-risk patients receiving DCD kidney grafts, for whom ATG is not clearly indicated.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16268</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16268</link>
        <title><![CDATA[Decisional preferences and distress among kidney transplant recipients with impaired graft function]]></title>
        <pubdate>2026-06-01T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Bilgin Osmanodja</author><author>Jakob Joachim Spencker</author><author>Ömer Ege Ömeroğlu</author><author>Zeineb Sassi</author><author>Sascha Eickmann</author><author>Roland Roller</author><author>Aljoscha Burchardt</author><author>Michael Hahn</author><author>Tabea Ott</author><author>Peter Dabrock</author><author>Sebastian Möller</author><author>Klemens Budde</author><author>Anne Herrmann</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16689</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16689</link>
        <title><![CDATA[Transplantation of older DCD livers in the machine perfusion era: a U.S. cohort study]]></title>
        <pubdate>2026-05-29T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Emmanouil Giorgakis</author><author>Ioannis A. Ziogas</author><author>Dimitrios Moris</author><author>Dimitrios N. Varvoglis</author><author>Charalampos Theocharopoulos</author><author>Dor Yoeli</author><author>Megan A. Adams</author><author>Andrew S. Barbas</author><author>Martin I. Montenovo</author><author>Melissa Chen</author><author>Sorabh Kapoor</author><author>Esteban Calderon</author><author>Andrew M. Moon</author><author>Sasha Deutch-Link</author><author>Hersh Shroff</author><author>Neil D. Shah</author><author>Oren K. Fix</author><author>A. Sidney Barritt</author><author>Amit K. Mathur</author><author>Trevor Nydam</author><author>Chirag S. Desai</author><author>Paulo N. Martins</author><author>Andrea Schegel</author>
        <description><![CDATA[Donation after circulatory death (DCD) livers increasingly use machine perfusion (MP). This study evaluates MP’s impact on older DCD livers based on data from the United Network for Data Sharing, covering all first adult DCD liver transplants (2016–2025). The cohort, divided into pre-MP and MP eras (separated by the FDA approval of the first normothermic MP platform in 2021), showed accelerated growth in DCD liver transplants during the MP era. Donors ≥60 rose 7.8-fold, including donors ≥70 (a USA first). By 2025, DCD livers accounted for 43.2%, with 61.35% from donors ≥50. Normothermic regional perfusion (NRP) (3.0%–16.5%), NMP (2.1%–38.9%), and sequential NRP-NMP (0.1%–10.7%) increased significantly (p < 0.001). The MP era was associated with a decrease in median waitlist time from 112 to 62 days (p < 0.001). Early graft survival was similar across ages. For ages 50–59, 1- and 3-year survivals were 87.9%/78.4% pre-MP and 90.1%/78.8% in the MP era. For 60–69, survival was 85.0%/80.6% pre-MP and 90.0%/71.3% in the MP era. DCD LTs for ≥70 were limited to the MP era with 87.8% 1-year survival. Multivariable Cox regression showed that static cold storage (HR = 1.29), donor age 50–69 versus 18–49, and recipient age (HR = 1.01) increased the risk of graft loss after adjustment. MP is associated with an increased number of older DCD liver transplants and acceptable early graft survival.]]></description>
      </item>
      </channel>
    </rss>